ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT)

Every figure this model derived for ADPT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 3,025,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 344,255,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 420,563,000 AssetsCurrent 2026-06-30
current liabilities 87,712,000 LiabilitiesCurrent 2026-06-30
equity 142,914,000 StockholdersEquity 2026-06-30
interest expense 11,508,000 InterestExpense 2026-06-30
ocf -21,009,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 308,081,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 49,024,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ADPT on one particular measure came for.

RatioValue
cash operating margin8.44
current ratio12.21
current ratio reported4.79
deferred revenue growth-3.7
dilution pct3.14
fcf margin-7.8
growth cv1.02
interest cover-3.26
operating margin-12.16
owner earnings margin-23.71
revenue growth50.13
revenue growth per share45.55
rule of 4037.97
sbc pct revenue15.91

What to be careful about

What this model itself distrusts about ADPT's figures. Written by the derivation as it ran, not added afterwards.